Rosiglitazone treatment alleviates inflammation and improves liver function in overweight women with polycystic ovary syndrome: a randomized placebo-controlled study

In a randomized, placebo-controlled study, we studied the effects of 4 months' treatment with rosiglitazone on low-grade inflammation, liver function, lipid levels, and blood pressure in 30 overweight women with polycystic ovary syndrome. Rosiglitazone significantly decreased serum C-reactive p...

Full description

Saved in:

Bibliographic Details
Published in:	Fertility and sterility Vol. 87; no. 1; p. 202
Main Authors:	Rautio, Katrina, Tapanainen, Juha S, Ruokonen, Aimo, Morin-Papunen, Laure C
Format:	Journal Article
Language:	English
Published:	United States 01.01.2007
Subjects:	Adolescent Adult Female Humans Hypoglycemic Agents - administration & dosage Inflammation - drug therapy Liver Diseases - drug therapy Obesity - drug therapy Polycystic Ovary Syndrome - drug therapy Thiazolidinediones - therapeutic use Treatment Outcome
ISSN:	1556-5653, 1556-5653
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	In a randomized, placebo-controlled study, we studied the effects of 4 months' treatment with rosiglitazone on low-grade inflammation, liver function, lipid levels, and blood pressure in 30 overweight women with polycystic ovary syndrome. Rosiglitazone significantly decreased serum C-reactive protein levels, white blood cell count, and alanine aminotransferase enzyme activity but did not affect lipid or blood pressure levels. Placebo had no effect on any parameters.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3
ISSN:	1556-5653 1556-5653
DOI:	10.1016/j.fertnstert.2006.05.061